Given that multiple sodium channels often contribute to chronic pain conditions, therapeutic leads targeting multiple NaV channels could be advantageous; for example, chronic visceral pain may be best treated by a NaV1.1/NaV1.7/NaV1.8 inhibitor, while diabetic neuropathy may be best treated by a NaV1.3/NaV1.6/NaV1.7 inhibitor. This evidence concerns the gene SCN9A and diabetic neuropathy.